Infect Chemother.  2014 Mar;46(1):30-34. 10.3947/ic.2014.46.1.30.

GeneXpert MTB/RIF Testing in the Management of Patients with Active Tuberculosis; A Real Life Experience from Saudi Arabia

• Omrani AS
• Al-Otaibi
• Al-Ateah S
• Al-Onazi F
• Baig K
• El-Khizzi
• Albarrak A

• KMID: 2170457
• DOI: http://doi.org/10.3947/ic.2014.46.1.30

Abstract

BACKGROUND
GeneXpert MTB/RIF is a real-time PCR assay with established diagnostic performance in pulmonary and extra-pulmonary forms of tuberculosis. The aim of this study was to assess the contribution of GeneXpert MTB/RIF assay to the management of patients with any form of active tuberculosis in a single large tertiary center in Saudi Arabia, with a special focus on the impact on time to start of antituberculous therapy compared with Ziehl-Neelsen (ZN) smears and mycobacterial cultures.
MATERIALS AND METHODS
Clinical, radiological and laboratory records for all patients who were commenced on antituberculous therapy between March 2011 and February 2013 were retrospectively reviewed.
RESULTS
A total of 140 patients were included, 38.6% of which had pulmonary tuberculosis. GeneXpert MTB/RIF was requested for only 39.2% of patients and was the only reason for starting antituberculous therapy for only 12.1%. The median time to a positive GeneXpert MTB/RIF result was 0 days (IQR 3) compared with 0 day (IQR 1) for smear microscopy (P > 0.999) and 22 days (IQR 21) for mycobacterial cultures (P < 0.001). No patients discontinued antituberculous therapy because of a negative GeneXpert MTB/RIF result.
CONCLUSIONS
In a setting wherein physicians are highly experienced in the diagnosis and treatment of tuberculosis, GeneXpert MTB/RIF was remarkably under-utilized and had only a limited impact on decisions related to starting or stopping antituberculous therapy. Cost-effectiveness and clinical utility of routine testing of all smear-negative clinical samples submitted for tuberculosis investigations by GeneXpert MTB/RIF warrant further study.

Keyword

GeneXpert MTB/RIF; Saudi Arabia; Tuberculosis

MeSH Terms

Diagnosis
Humans
Life Change Events*
Microscopy
Real-Time Polymerase Chain Reaction
Retrospective Studies
Saudi Arabia*
Tuberculosis*
Tuberculosis, Pulmonary

Figure

• 

  Figure 1 Basis for diagnosis of tuberculosis (TB) at start of anti-tuberculous therapy; number (percentage).

Reference

1. World Health Organization. Global Tuberculosis Report 2012. Geneva, Switzerland: World Health Organization;2012. Accessed 25 October 2013. Available at: http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf.

2. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010; 375:1814–1829.

3. Mathew P, Kuo YH, Vazirani B, Eng RH, Weinstein MP. Are three sputum acid-fast bacillus smears necessary for discontinuing tuberculosis isolation? J Clin Microbiol. 2002; 40:3482–3484.

4. van Kampen SC, Anthony RM, Klatser PR. The realistic performance achievable with mycobacterial automated culture systems in high and low prevalence settings. BMC Infect Dis. 2010; 10:93.

5. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med. 2009; 30:701–716.

6. Coll P, Garrigó M, Moreno C, Marti N. Routine use of Gen-Probe Amplified Mycobacterium tuberculosis Direct (MTD) test for detection of Mycobacterium tuberculosis with smear-positive and smear-negative specimens. Int J Tuberc Lung Dis. 2003; 7:886–891.

7. Laraque F, Griggs A, Slopen M, Munsiff SS. Performance of nucleic acid amplification tests for diagnosis of tuberculosis in a large urban setting. Clin Infect Dis. 2009; 49:46–54.

8. Lawn SD, Nicol MP. Xpert(R) MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011; 6:1067–1082.

9. World Health Organization. Policy statement : automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, Switzerland: World Health Organization;2011. Accessed 25 October 2013. Available at: http://whqlibdoc.who.int/publications/2011/9789241501545_eng.pdf.

10. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363:1005–1015.

11. Hillemann D, Rüsch-Gerdes S, Boehme C, Richter E. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol. 2011; 49:1202–1205.

12. Tortoli E, Russo C, Piersimoni C, Mazzola E, Dal Monte P, Pascarella M, Borroni E, Mondo A, Piana F, Scarparo C, Coltella L, Lombardi G, Cirillo DM. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J. 2012; 40:442–447.

13. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. Feasibility, diagnostic accuracy, and effectiveness of decent ralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011; 377:1495–1505.

14. Abouzeid MS, Zumla AI, Felemban S, Alotaibi B, O'Grady J, Memish ZA. Tuberculosis trends in Saudis and non-Saudis in the Kingdom of Saudi Arabia - a 10 year retrospective study (2000-2009). PLoS ONE. 2012; 7:e39478.

15. Al-Ateah SM, Al-Dowaidi MM, El-Khizzi NA. Evaluation of direct detection of Mycobacterium tuberculosis complex in respiratory and non-respiratory clinical specimens using the Cepheid Gene Xpert(R) system. Saudi Med J. 2012; 33:1100–1105.

16. Kranzer K. Improving tuberculosis diagnostics and treatment. Lancet. 2011; 377:1467–1468.